Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation

Debyani Chakravarty, Elmer Santos, Mabel Ryder, Jeffrey A. Knauf, Xiao Hui Liao, Brian L. West, Gideon Bollag, Richard Kolesnick, Tin Htwe Thin, Neal Rosen, Pat Zanzonico, Steven M. Larson, Samuel Refetoff, Ronald Ghossein, James A. Fagin

Research output: Contribution to journalArticle

186 Citations (Scopus)

Abstract

Advanced human thyroid cancers, particularly those that are refractory to treatment with radioiodine (RAI), have a high prevalence of BRAF (v-raf murine sarcoma viral oncogene homolog B1) mutations. However, the degree to which these cancers are dependent on BRAF expression is still unclear. To address this question, we generated mice expressing one of the most commonly detected BRAF mutations in human papillary thyroid carcinomas (BRAF V600E) in thyroid follicular cells in a doxycycline-inducible (dox-inducible) manner. Upon dox induction of BRAF V600E, the mice developed highly penetrant and poorly differentiated thyroid tumors. Discontinuation of dox extinguished BRAF V600E expression and reestablished thyroid follicular architecture and normal thyroid histology. Switching on BRAF V600E rapidly induced hypothyroidism and virtually abolished thyroid-specific gene expression and RAI incorporation, all of which were restored to near basal levels upon discontinuation of dox. Treatment of mice with these cancers with small molecule inhibitors of either MEK or mutant BRAF reduced their proliferative index and partially restored thyroid-specific gene expression. Strikingly, treatment with the MAPK pathway inhibitors rendered the tumor cells susceptible to a therapeutic dose of RAI. Our data show that thyroid tumors carrying BRAF V600E mutations are exquisitely dependent on the oncoprotein for viability and that genetic or pharmacological inhibition of its expression or activity is associated with tumor regression and restoration of RAI uptake in vivo in mice. These findings have potentially significant clinical ramifications.

Original languageEnglish (US)
Pages (from-to)4700-4711
Number of pages12
JournalJournal of Clinical Investigation
Volume121
Issue number12
DOIs
StatePublished - Dec 1 2011
Externally publishedYes

Fingerprint

Thyroid Neoplasms
Thyroid Gland
Neoplasms
Mutation
Gene Expression
Doxycycline
Oncogene Proteins
Mitogen-Activated Protein Kinase Kinases
Therapeutics
Hypothyroidism
Oncogenes
Sarcoma
Histology
Pharmacology

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Chakravarty, D., Santos, E., Ryder, M., Knauf, J. A., Liao, X. H., West, B. L., ... Fagin, J. A. (2011). Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. Journal of Clinical Investigation, 121(12), 4700-4711. https://doi.org/10.1172/JCI46382

Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. / Chakravarty, Debyani; Santos, Elmer; Ryder, Mabel; Knauf, Jeffrey A.; Liao, Xiao Hui; West, Brian L.; Bollag, Gideon; Kolesnick, Richard; Thin, Tin Htwe; Rosen, Neal; Zanzonico, Pat; Larson, Steven M.; Refetoff, Samuel; Ghossein, Ronald; Fagin, James A.

In: Journal of Clinical Investigation, Vol. 121, No. 12, 01.12.2011, p. 4700-4711.

Research output: Contribution to journalArticle

Chakravarty, D, Santos, E, Ryder, M, Knauf, JA, Liao, XH, West, BL, Bollag, G, Kolesnick, R, Thin, TH, Rosen, N, Zanzonico, P, Larson, SM, Refetoff, S, Ghossein, R & Fagin, JA 2011, 'Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation', Journal of Clinical Investigation, vol. 121, no. 12, pp. 4700-4711. https://doi.org/10.1172/JCI46382
Chakravarty, Debyani ; Santos, Elmer ; Ryder, Mabel ; Knauf, Jeffrey A. ; Liao, Xiao Hui ; West, Brian L. ; Bollag, Gideon ; Kolesnick, Richard ; Thin, Tin Htwe ; Rosen, Neal ; Zanzonico, Pat ; Larson, Steven M. ; Refetoff, Samuel ; Ghossein, Ronald ; Fagin, James A. / Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. In: Journal of Clinical Investigation. 2011 ; Vol. 121, No. 12. pp. 4700-4711.
@article{b6ad2ebe954540eeaed6afcdf3e13037,
title = "Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation",
abstract = "Advanced human thyroid cancers, particularly those that are refractory to treatment with radioiodine (RAI), have a high prevalence of BRAF (v-raf murine sarcoma viral oncogene homolog B1) mutations. However, the degree to which these cancers are dependent on BRAF expression is still unclear. To address this question, we generated mice expressing one of the most commonly detected BRAF mutations in human papillary thyroid carcinomas (BRAF V600E) in thyroid follicular cells in a doxycycline-inducible (dox-inducible) manner. Upon dox induction of BRAF V600E, the mice developed highly penetrant and poorly differentiated thyroid tumors. Discontinuation of dox extinguished BRAF V600E expression and reestablished thyroid follicular architecture and normal thyroid histology. Switching on BRAF V600E rapidly induced hypothyroidism and virtually abolished thyroid-specific gene expression and RAI incorporation, all of which were restored to near basal levels upon discontinuation of dox. Treatment of mice with these cancers with small molecule inhibitors of either MEK or mutant BRAF reduced their proliferative index and partially restored thyroid-specific gene expression. Strikingly, treatment with the MAPK pathway inhibitors rendered the tumor cells susceptible to a therapeutic dose of RAI. Our data show that thyroid tumors carrying BRAF V600E mutations are exquisitely dependent on the oncoprotein for viability and that genetic or pharmacological inhibition of its expression or activity is associated with tumor regression and restoration of RAI uptake in vivo in mice. These findings have potentially significant clinical ramifications.",
author = "Debyani Chakravarty and Elmer Santos and Mabel Ryder and Knauf, {Jeffrey A.} and Liao, {Xiao Hui} and West, {Brian L.} and Gideon Bollag and Richard Kolesnick and Thin, {Tin Htwe} and Neal Rosen and Pat Zanzonico and Larson, {Steven M.} and Samuel Refetoff and Ronald Ghossein and Fagin, {James A.}",
year = "2011",
month = "12",
day = "1",
doi = "10.1172/JCI46382",
language = "English (US)",
volume = "121",
pages = "4700--4711",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "12",

}

TY - JOUR

T1 - Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation

AU - Chakravarty, Debyani

AU - Santos, Elmer

AU - Ryder, Mabel

AU - Knauf, Jeffrey A.

AU - Liao, Xiao Hui

AU - West, Brian L.

AU - Bollag, Gideon

AU - Kolesnick, Richard

AU - Thin, Tin Htwe

AU - Rosen, Neal

AU - Zanzonico, Pat

AU - Larson, Steven M.

AU - Refetoff, Samuel

AU - Ghossein, Ronald

AU - Fagin, James A.

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Advanced human thyroid cancers, particularly those that are refractory to treatment with radioiodine (RAI), have a high prevalence of BRAF (v-raf murine sarcoma viral oncogene homolog B1) mutations. However, the degree to which these cancers are dependent on BRAF expression is still unclear. To address this question, we generated mice expressing one of the most commonly detected BRAF mutations in human papillary thyroid carcinomas (BRAF V600E) in thyroid follicular cells in a doxycycline-inducible (dox-inducible) manner. Upon dox induction of BRAF V600E, the mice developed highly penetrant and poorly differentiated thyroid tumors. Discontinuation of dox extinguished BRAF V600E expression and reestablished thyroid follicular architecture and normal thyroid histology. Switching on BRAF V600E rapidly induced hypothyroidism and virtually abolished thyroid-specific gene expression and RAI incorporation, all of which were restored to near basal levels upon discontinuation of dox. Treatment of mice with these cancers with small molecule inhibitors of either MEK or mutant BRAF reduced their proliferative index and partially restored thyroid-specific gene expression. Strikingly, treatment with the MAPK pathway inhibitors rendered the tumor cells susceptible to a therapeutic dose of RAI. Our data show that thyroid tumors carrying BRAF V600E mutations are exquisitely dependent on the oncoprotein for viability and that genetic or pharmacological inhibition of its expression or activity is associated with tumor regression and restoration of RAI uptake in vivo in mice. These findings have potentially significant clinical ramifications.

AB - Advanced human thyroid cancers, particularly those that are refractory to treatment with radioiodine (RAI), have a high prevalence of BRAF (v-raf murine sarcoma viral oncogene homolog B1) mutations. However, the degree to which these cancers are dependent on BRAF expression is still unclear. To address this question, we generated mice expressing one of the most commonly detected BRAF mutations in human papillary thyroid carcinomas (BRAF V600E) in thyroid follicular cells in a doxycycline-inducible (dox-inducible) manner. Upon dox induction of BRAF V600E, the mice developed highly penetrant and poorly differentiated thyroid tumors. Discontinuation of dox extinguished BRAF V600E expression and reestablished thyroid follicular architecture and normal thyroid histology. Switching on BRAF V600E rapidly induced hypothyroidism and virtually abolished thyroid-specific gene expression and RAI incorporation, all of which were restored to near basal levels upon discontinuation of dox. Treatment of mice with these cancers with small molecule inhibitors of either MEK or mutant BRAF reduced their proliferative index and partially restored thyroid-specific gene expression. Strikingly, treatment with the MAPK pathway inhibitors rendered the tumor cells susceptible to a therapeutic dose of RAI. Our data show that thyroid tumors carrying BRAF V600E mutations are exquisitely dependent on the oncoprotein for viability and that genetic or pharmacological inhibition of its expression or activity is associated with tumor regression and restoration of RAI uptake in vivo in mice. These findings have potentially significant clinical ramifications.

UR - http://www.scopus.com/inward/record.url?scp=84055191090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84055191090&partnerID=8YFLogxK

U2 - 10.1172/JCI46382

DO - 10.1172/JCI46382

M3 - Article

C2 - 22105174

AN - SCOPUS:84055191090

VL - 121

SP - 4700

EP - 4711

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 12

ER -